Agenda

Overview | Mission
Green sustainability
Social responsibility
Governance
Sartorius at a glance

- **€4.17bn**
  Sales revenue 2022

- **~18%**
  Sales CAGR\(^1\) 2012-2022

- **33.8%**
  EBITDA margin\(^2\) 2022

- **60+**
  Locations worldwide,
  HQ in Göttingen, Germany

- **~16,000**
  Employees 12/2022

**Two divisions with clear focus on attractive biopharma and life science industry**

- **80%**
  Bioprocess Solutions Division

- **~€4.17bn**
  Sales 2022

- **20%**
  Lab Products & Services Division

- **~85%**
  with life science customers

---

1. In constant currencies
2. Excluding extraordinary items
Supporting customers from the initial idea in the lab to commercial-scale production of biologics
Long-term value creation by focusing on four material topics

1. Economic performance
   - Advance innovation, contribute to medical progress

2. Ecologic performance
   - Protect the environment by reducing emissions, waste and water use
   - Assuming responsibility for our products throughout their life cycles

3. Social performance
   - Find and retain employees, provide good working conditions
   - Protect health and safety, promote continuous development

4. Governance performance
   - Responsible corporate governance and compliance
   - Respect for human rights throughout the supply chain
At the core of our business: “Good health and well-being”

Our mission

We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine.
Health is one of the most relevant global topics

**Growing and aging population**

<table>
<thead>
<tr>
<th>Year</th>
<th>Population over 65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>~0.8bn</td>
</tr>
<tr>
<td>2050</td>
<td>~1.6bn</td>
</tr>
</tbody>
</table>

**Development and manufacturing of drugs are time-consuming and costly**

- Research: >€2bn
- Commercial production: 1 out of 10,000
- Time: > of 10 years

1 United Nations: World Population Prospects, 2022  
2 Based on data from the Tufts Center for the Study of Drug Development and the Association of the British Pharmaceutical Industry
The challenge: Many innovative biotech medications are very expensive

**Rheumatism**
- Monoclonal antibody therapy
  - \(~€12,000\)
  - Annual cost of treatment in Germany

**Blood cancer**
- CAR-T cell therapy
  - \(~€280,000\)
  - Cost per treatment in Europe

**Hemophilia**
- Gene therapy
  - \(~€3.5\ mn\)
  - Cost per treatment in the USA
Three drivers for innovation: The key to achieve ESG targets

**Product development**
in areas of own core competencies

**Acquisitions**
of complementary and differentiating technologies

- Bioanalytics
- Downstream processing
- Cell and gene therapies

**Cooperations**
with partners that are leading in areas of future relevance

- Advanced materials
- Process automation & digitization
- 3D cell printing technology
- Bioanalytics

Product launch
Sartobind® Rapid A
Sartorius’ technologies enable researchers to achieve results faster, ...

Example: digitalization and automation of laboratory processes

- More experiments with lower error rate
- Data and analysis for better decisions
- Shortening time-to-clinic

Saves more than 5 weeks in the selection of cell clones
... and increase yield and efficiency in biopharma production

Example: new, innovative bioprocess technologies

<table>
<thead>
<tr>
<th>Product</th>
<th>Benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIMmultus®</td>
<td>Downstream processing time reduced by 60%</td>
</tr>
<tr>
<td></td>
<td>Significantly higher yields of viral vectors required for gene therapies</td>
</tr>
<tr>
<td>Sartobind® Rapid A</td>
<td>20x Higher productivity compared to classical column chromatography</td>
</tr>
<tr>
<td></td>
<td>&gt;30% Cost reduction in clinical manufacturing</td>
</tr>
</tbody>
</table>
A strong lever of impact on green aspects: Our customers’ operations

Global GHG emissions in CO₂ equivalents in 2021\(^1\)

>50 billion tons

Of these related to the healthcare sector\(^2\)

~4-5%

Attributable emissions of Sartorius\(^3\) make up

~0.025%

---

1 UN Environment Programme „Emissions Gap Report 2022“, preliminary estimate  
2 According to World Economic Forum June 2021  
3 Own calculations
SU technologies help to reduce water and energy consumption at the customers’ sites

Water consumption\(^1\) ~ -30%

Energy consumption\(^1\) ~ -30%

Celsius\(^\circ\) FFT Freeze & Thaw Solutions
Maxicaps\(^\circ\) Sterile filter
Sartopore\(^\circ\) Platinum
Flexsafe\(^\circ\)
Linkit\(^\circ\) AX

1 Based on data from Flanagan et al (2011). LCA of a mAb process at 2,000 L scale.
Process intensification leads to higher efficiency and less eco impact

Process Mass Intensification\(^1\) -50%

\[
\text{PMI} = \frac{\text{Total raw materials, consumables and water (kg)}}{\text{Product (kg)}}
\]

1 Data from in-house case study: 300 kg/year and 1,500 kg/year throughputs. PMI measured for a traditional stainless steel fed batch process (SS 15kL), and a process intensification scenario (SU dynamic perfusion process with downstream multi-column chromatography). Data was generated using BioSolve modeling software.
Data analytics solutions support customers in further CO₂ reduction

**Success Story**

Implementation of Umetrics® Suite data analytics tools at Michigan University helps increase process efficiency and reduces carbon footprint significantly.

**Phase 1** | prevented
780 tons CO₂e

**Phase 2** | aims to prevent
10,000 tons CO₂e
Agenda

Overview | Mission

Green sustainability

Social responsibility

Governance
Sartorius' environmental fields of action at its own operations
Only a small portion of emissions under own control

**Scope 1**

**Direct emissions**
from sources for which we are responsible, such as our manufacturing processes or company vehicles.

~10% of total emissions

**Scope 2**

**Indirect emissions**
from purchased electricity, steam, heating and cooling at our 60+ sites worldwide.

~90% of total emissions

**Scope 3**

**Indirect emissions**
from sources upstream and downstream in the value chain that we only partially control, e.g. purchased goods/services, product life cycle, employee commuting.

~90% of total emissions
Ambitious climate targets until 2030

~10% p.a. reduction of CO₂eq emission intensity on average by 2030

Spending of ~1% of revenue p. a.

~ -70% reduction of avoidable emissions in Scope 1 and 2 until 2030

1 Process emissions from membrane manufacturing are currently considered unavoidable based on available technology; base year 2019
CO₂ reduction levers across the value chain

**Upstream (Scope 3)**
- Purchased goods & services
  - Eco-design products & packaging
  - Efficiency in manufacturing
  - Supplier engagement
- Upstream incl. int. transportation
  - Eco-design packaging
  - Transport
    - Frequency
    - Distance
    - Freight mode
    - Fuels
  - Production process steps
- Business travel
  - Reduce travel
  - Sustainable travel
- Manufacturing & warehousing
  - Improve energy efficiency
  - Produce clean energy
  - Procure renewable energy

**Production Scope 1&2**
- Eco-design packaging
  - Transport
    - Frequency
    - Distance
    - Freight mode
    - Fuels
- Down-stream transportation
- Product use & end of life
  - Eco-design products & packaging
  - Process intensification

**Downstream (Scope 3)**
- Other (capital goods, employee commuting, buildings)
- Buildings & construction
- Capital goods
- Commute sustainably
Expanding renewable energy capacity at Sartorius’ sites worldwide

North America
- Yauco, PR
  - In % of group: ~14
  - Renewable energy %: <0.5
  - Outlook: >90% in 2030

- Aubagne, FR
  - In % of group: ~5
  - Renewable energy %: ~94
  - Outlook: 100% in 2025

Beijing, CN
- In % of group: ~6
- Renewable energy %: 0
- Outlook: 100% in 2030

Bangalore, IN
- In % of group: ~2
- Renewable energy %: ~10
- Outlook: >60% in 2023

North America
- Royston, Stonehouse, UK
  - In % of group: ~3
  - Renewable energy %: ~90% in 2027

- Helsinki, Kajaani FI
  - In % of group: ~4
  - Renewable energy %: ~52
  - Outlook: 100% in 2030

- Göttingen, DE
  - In % of group: ~49
  - Renewable energy %: ~45
  - Outlook: 100% in 2030

- M’hamdia, TN
  - In % of group: ~3
  - Renewable energy %: 0
  - Outlook: 100% in 2030

Expansion of renewable energy capacity depending on availability of renewable energy sources

* FY 2022
Flexsafe® - first film designed for recycling

A milestone on the way to circularity

- From 20ml to 2,000l, Flexsafe® is the first film in the industry designed for recycling in a standard polyethylene waste stream.
- Used in bioprocessing for non-hazardous applications, it can technically be recycled into raw materials with quality equivalent to pristine grades of polymers.

Partners

1. SANOFI
2. VEOLIA
3. SUDPACK
Materials and circularity: Transitioning towards a circular economy

Our ambitions

We aim to optimize the selection and use of materials to improve our products’ environmental footprint.

- Optimize use of resources
- Avoid packaging waste
- Recycle production waste
- Life cycle analysis

75%
Current plastics recycling rate

Biopharma accounts for
~ 0.01% of total plastic waste

1st company in the industry to sign
Current projects regarding the single-use technology life cycle

<table>
<thead>
<tr>
<th>Feedstock</th>
<th>Beginning of life</th>
<th>Production</th>
<th>Product usage</th>
<th>Product end of life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fossil</td>
<td>Naphtha Cracker</td>
<td>Resins</td>
<td>Product</td>
<td>Scrap Reduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Packaging</td>
<td>Recycling Options</td>
</tr>
</tbody>
</table>

1. Alternative Feedstock
2. Less Material
3. Scrap Reduction Program
4. PMI
5. Recycling Options
Initiatives to improve waste management in Aubagne

Enhanced film recyclability ➤ Reduced film consumption ➤ Improved waste collection and sorting ➤ Increased waste recycling

Total Waste (t/1000 Units)

-17%

2018: 0.97
2019: 0.89
2020: 0.63
2021: 0.52

Waste Processing

- Landfill
- Energy Recovery
- Waste Recycling

2018
2019
2020
2021

<table>
<thead>
<tr>
<th>Total Waste</th>
<th>Waste Recycling</th>
<th>Energy Recovery</th>
<th>Landfill</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018: 17%</td>
<td>26%</td>
<td>57%</td>
<td>0%</td>
</tr>
<tr>
<td>2019: 15%</td>
<td>19%</td>
<td>66%</td>
<td>0%</td>
</tr>
<tr>
<td>2020: 12%</td>
<td>4%</td>
<td>84%</td>
<td>0%</td>
</tr>
<tr>
<td>2021: 10%</td>
<td>6%</td>
<td>84%</td>
<td>0%</td>
</tr>
</tbody>
</table>

1 Figure taken from: Vachette, Elisabeth & Fenge, Christel & Cappia, Jean Marc & Delaunay, Lucie & Greller, Gerhard & Barbaroux, Magali. (2014). Robust and convenient single-use processing: The superior strength and flexibility of flexsafe bags. 12.
Water and wastewater: Improve water efficiency in own operations

The ambitions
- Reduce use of drinking water, increase use of rainwater
- Decrease wastewater, increase water recycling
- Optimization of production cycles with solvents

Water is primarily used in BPS for membrane production and modification.
Solvent and water reuse at the Yauco plant

4 distillation columns
Processing capacity: 16,500 kg/day of spent solvent (oldware)

- 3.9 million kg of oldware processed for reuse
- 11.9 million litres of water processed for reuse
- 90% recovery of 2-pyrrolidone (2P) from oldware
- 98% recovery of Isopropanol (IPA) from oldware

Base April 2022
Supply chain due diligence act: Risk assessment

Hard facts risk assessment

Country risks
> 90%\(^1\)

3\(^{rd}\) party assessment
> 50%\(^1\)

Code of Conduct
> 40%\(^1\)

Certificates

Soft facts risk assessment

Sustainability report/strategy

Commitment to SDGs

Member Sustainability Association

Actions with supplier

If high risk

Improvement actions

1 Coverage in terms of spend as of June 2023
Agenda

Overview | Mission
Green sustainability
Social responsibility
Governance
People at Sartorius: A growing team of >15,000 people

- 3,652 New hires in 2022
- 245 New employees from M&A in 2022
- 40% Less than 2 years in the company

Many opportunities to grow with the company

- ~2,000 new jobs per year
- 55% of management positions filled internally

New hires in 2022:

- 3,652

New employees from M&A in 2022:

- 245

Less than 2 years in the company:

- 40%

Bar chart showing new hires from 2018 to 2022:

- 2018: 8,125
- 2019: 9,036
- 2020: 10,637
- 2021: 13,832
- 2022: 15,942

Many opportunities to grow with the company:

- 55% of management positions filled internally
An increasingly diverse team that brings in a variety of perspectives

<table>
<thead>
<tr>
<th>International workforce</th>
<th>Balanced age structure</th>
<th>Share of women at a high level</th>
</tr>
</thead>
<tbody>
<tr>
<td>119 Nationalities</td>
<td>≤29 years: 21%</td>
<td>39% Share of women in the entire workforce</td>
</tr>
<tr>
<td>70% Non-German managers</td>
<td>30-39 years: 36%</td>
<td>35% Share of women at 1st and 2nd management levels</td>
</tr>
<tr>
<td>3 Nationalities on the four-member Board</td>
<td>40-49 years: 23%</td>
<td>47% Female executives on 1st level below the Board</td>
</tr>
<tr>
<td></td>
<td>≥50 years: 20%</td>
<td></td>
</tr>
</tbody>
</table>

Ø 39 years age

As of December 31, 2022
High employee satisfaction reflected internally and externally

- 90% say they contribute to the company’s mission
- 85% are proud to work for Sartorius
- 84% agree that Sartorius respects and strengthens diversity

3.8 ★★★★★☆
glassdoor
Intern. competitors Ø 3.7

4.0 ★★★★★☆
kununu
DAX40 Ø 3.7

As of Q3 2022
Promoting science, education and innovation – also beyond our walls

Cell Culture Facility at Penn State | Supporting groundbreaking research with $1.5 million

Life Science Factory | Promoting startups and attract entrepreneurs in life sciences

LifeScienceXplained | Creating a stage for science communicators since 2021
Engaged in humanitarian aid and disaster relief globally

**action medeor** provides medical care to humanitarian organizations and health centers all over the world.

Our latest commitments include

- Support for earthquake victims of in Türkiye and Syria
- Humanitarian aid for the people of Ukraine
- Healthcare support in Guatemala
- Pharmaceutical training in West Africa
Agenda

Overview | Mission
Green sustainability
Social responsibility
Governance
Sartorius actively manages its sustainability impacts, risks and opportunities at its own operations.

**Existing and upcoming EU regulation**

- Corporate Sustainability Due Diligence Directive (CSDDD)
- Taxonomy Regulation
- Corporate Sustainability Reporting Directive (CSRD)

**Annual management process**

1. Identify relevant topics
2. Assess material IRO
3. Define measures / action plan
4. Monitoring
5. Reporting
6. Policy review
Multiple data points to be consistently tracked consistently

<table>
<thead>
<tr>
<th>Reporting topics</th>
<th>Challenges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Climate</td>
<td>&gt; 80 disclosure requirements</td>
</tr>
<tr>
<td>Water</td>
<td>&gt; 1,000 data points</td>
</tr>
<tr>
<td>Biodiversity</td>
<td>17 GHG emission categories</td>
</tr>
<tr>
<td>Own workforce</td>
<td>Data from multiple sources</td>
</tr>
<tr>
<td>Communities</td>
<td>Concepts for data calculation and estimates</td>
</tr>
<tr>
<td>Business conduct</td>
<td>Data governance and enrichment projects</td>
</tr>
<tr>
<td>Workers in the value chain</td>
<td>Continuous data improvement</td>
</tr>
<tr>
<td>Consumers</td>
<td></td>
</tr>
</tbody>
</table>

Reporting partially based on external data which can be subject to changes and specifications; therefore, continuous and retrospective restatements of certain data might be necessary.
Alignment of 2022 turnover & expenditures with EU taxonomy

Total sales revenues in %

- Not Taxonomy-eligible: 100%
- Taxonomy-eligible but not aligned: 0%
- Taxonomy-aligned: 0%

Total CapEx in %

- Not Taxonomy-eligible: 81%
- Taxonomy-eligible but not aligned: 18%
- Taxonomy-aligned: 1%

Total OpEx in %

- Not Taxonomy-eligible: 18%
- Taxonomy-eligible but not aligned: 81%
- Taxonomy-aligned: 1%

All figures rounded

1 Sartorius does not have any taxonomy-eligible economic activities for which it would currently have been possible to assess compliance with the technical screening criteria as legislation only addresses particularly relevant economic activities for the achievement of the environmental objectives in the field of climate change mitigation and climate change adaptation, i.e. only a limited range of industries is covered.
Sustainability ratings and partnerships

Listed in:

**DAX 50 ESG**

**Sustainability ratings**

- **MSCI**: AA
- **ecovadis**: Silver
- **Sustainalytics**: Low risk
- **CDP**: B

Memberships and cooperation in internationally renowned initiatives and platforms:

- Sustainable Development Goals
- Econsense
- European Plastics Pact
- Integrity Next
- IPPI
- PSCl
- NIMBL
- BioPhorum
- DFK
- Charta der Vielfalt
- German Research Center for Artificial Intelligence
- Healthcare Businesswomen’s Association
### The legal & operational structure

<table>
<thead>
<tr>
<th>Sartorius AG (~68.4m shares)</th>
<th>Stock market listed in Germany&lt;sup&gt;1&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ordinary shares (~34.2m shares)</strong></td>
<td>~55% Administered by executor</td>
</tr>
<tr>
<td></td>
<td>~38% Bio-Rad Laboratories</td>
</tr>
<tr>
<td></td>
<td>~7% Free float</td>
</tr>
<tr>
<td><strong>Preference shares (~34.2m shares)</strong></td>
<td>~72% Free float</td>
</tr>
<tr>
<td></td>
<td>~28% Bio-Rad Laboratories</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sartorius Stedim Biotech S.A.</th>
<th>Stock market listed in France</th>
</tr>
</thead>
<tbody>
<tr>
<td>~91.2m shares</td>
<td>~74% Sartorius AG</td>
</tr>
<tr>
<td>~26% Free float</td>
<td>~74% Sartorius AG</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other Sartorius subsidiaries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bioprocess Solutions division</td>
</tr>
<tr>
<td>Lab Products &amp; Services division</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sartorius Group operational setup</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary shares (~34.2m shares)</td>
</tr>
<tr>
<td>Preference shares (~34.2m shares)</td>
</tr>
</tbody>
</table>

<sup>1</sup> The ownership relates to outstanding shares and thus excludes treasury shares. Information on shareholdings and shares in free float pursuant to the disclosure requirements of Sections 33 et seq. of the German Securities Trading Act (WpHG) and the shareholders’ own disclosures. The legal disclosure requirements refer only to voting shares and not to non-voting preference shares.
Executive Board of Sartorius AG

Joachim Kreuzburg, CEO
Joined Sartorius in 1999
Member of the Board since 2002
Group Strategy, Corporate
Research, Human Resources, Legal
& Compliance, Communications,
Sustainability

René Fáber
Joined Sartorius in 2002
Member of the Board since 2019
Bioprocess Solutions Division

Alexandra Gatzemeyer
Joined Sartorius in 2005
Member of the Board since May 1,
2023
Lab Products & Services Division

Rainer Lehmann, CFO
Joined Sartorius in 19991
Member of the Board since 2017
Finance, Information Technology,
Data Management, Corporate
Sourcing

1 Employment outside the Sartorius Group from 2004-2006
Two-tier Board system of Sartorius AG – Supervisory Board and its committees

- Twelve members, half of the members are shareholders` representatives and half are employees` representatives

### Executive Task Committee
- Dr. Lothar Kappich (Chairman)
- Annette Becker
- Prof. Dr. Klaus Rüdiger Trützschler
- Manfred Zaffke

### Nomination Committee
- Dr. Daniela Favoccia
- Dr. Lothar Kappich
- Prof. Dr. Klaus Rüdiger Trützschler

### Audit Committee
- Prof. Dr. Klaus Rüdiger Trützschler (Chairman)
- Dietmar Müller
- Dr. Lothar Kappich
- Manfred Zaffke

### Conciliation Committee
- Dr. Lothar Kappich (Chairman)
- Annette Becker
- Prof. Dr. Klaus Rüdiger Trützschler
- Manfred Zaffke
### One-tier Board of Sartorius Stedim Biotech S.A. subgroup

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Share of independent members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Joachim Kreuzburg</td>
<td>Chairman</td>
<td>43%</td>
</tr>
<tr>
<td>Dr. René Fáber</td>
<td>CEO</td>
<td>75%</td>
</tr>
<tr>
<td>Christelle Baudère</td>
<td>Employee representative</td>
<td>75%</td>
</tr>
<tr>
<td>Pascale Boissel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susan Dexter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anne-Marie Graffin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lothar Kappich</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Henri Riey</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. René Fáber</td>
<td>CEO</td>
<td>75%</td>
</tr>
<tr>
<td>Christelle Baudère</td>
<td>Employee representative</td>
<td>75%</td>
</tr>
<tr>
<td>Pascale Boissel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susan Dexter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anne-Marie Graffin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lothar Kappich</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Henri Riey</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Audit Committee**
- ●
- ●
- ●
- ●

**Remuneration & Nomination Committee**
- ●
- ●
- ●
- ●

**Independence**
- ●
- ●
- ●
## ESG aspects included in executive remuneration

<table>
<thead>
<tr>
<th>Remuneration components</th>
<th>Structure of the remuneration components</th>
<th>Maximum bonus (in % of the target amount)</th>
<th>Maximum Remuneration</th>
<th>Further benefits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed remuneration</td>
<td>Basic remuneration</td>
<td>100 %</td>
<td>Maximum amount of all cash remuneration components for the respective fiscal year</td>
<td>Compensation for post-contractual non-compensation clause (50% of most recent remuneration)</td>
</tr>
<tr>
<td>Retirement benefits</td>
<td>Basic amount</td>
<td>100 %</td>
<td></td>
<td>Clawback</td>
</tr>
<tr>
<td></td>
<td>Additional amount (matching contribution)</td>
<td>120 %</td>
<td></td>
<td>Severance cap in the event of early contract termination</td>
</tr>
<tr>
<td>Short-term variable remuneration</td>
<td>Sales revenue</td>
<td>Order Intake (Group and/or division)</td>
<td>120 %</td>
<td>Proportional grant date fair value of share-based payment for the respective fiscal year</td>
</tr>
<tr>
<td></td>
<td>Underlying EBITDA (Group and/or division)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ratio of net dept to underlying EBITDA (Group)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Employee Net Promoter Score (Group)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-term variable remuneration</td>
<td>Consolidated net profit</td>
<td>120 %</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reduction of CO²-EEQ emission Intensity</td>
<td>120 %</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panton stock units</td>
<td>250 %</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Share-based payment</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Share-based payment                          | One-time allotment; afterwards, no measurement of inflow                      |                                          |                                                                                      |                                                                                  |
To Sartorius, sustainability means operating responsibly over the long term – with respect to business partners, employees and society as well as to natural resources. Learn more about our commitment:

Sustainability Report 2022

Please click below for further financial information:

- Half Year Report H1 2023
- Earnings Release Q1 2023
- Annual Report FY 2022
Contacts and Financial calendar

Petra Kirchhoff
Head of Corporate Communications & IR
+49.551.308.1686
petra.kirchhoff@sartorius.com

Petra Müller
Head of Investor Relations
+49.551.308.6035
petra.mueller2@sartorius.com

Mirko Koch
Manager Investor Relations
+49.551.308.2402
mirko.koch@sartorius.com

Sartorius Corporate Administration GmbH
Otto-Brenner-Straße 20
37079 Göttingen, Germany

- **September 5, 2023**
  Commerzbank & Oddo BHF Annual Corp. Conference | Frankfurt a. Main

- **September 8, 2023**
  Wells Fargo Healthcare Conference | Everett MA

- **September 11, 2023**
  Morgan Stanley Healthcare Conference | New York

- **September 19, 2023**
  Berenberg / Goldman Sachs German Corporate Conf. | Munich

- **September 20, 2023**
  Baader Investment Conference | Munich

- **October 19, 2023**
  Publication nine-months 2023 Results

- **November 9, 2023**
  Societe Generale European ESG Conference | virtual
Disclaimer

This presentation contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. Throughout this presentation, differences may be apparent as a result of rounding during addition.